Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Bristol-Myers"

68 News Found

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development
People | July 31, 2025

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development

He most recently served as Chief Medical Officer of AstraZeneca and Alexion


Bristol Myers Squibb and Bain Capital launch biotech company NewCo
News | July 31, 2025

Bristol Myers Squibb and Bain Capital launch biotech company NewCo

NewCo’s pipeline includes five investigational medicines


Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
Diagnostic Center | July 19, 2025

Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl

Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use


FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels
Drug Approval | June 28, 2025

FDA approves removal of REMS programs within Bristol Myers Squibb’s cell therapy labels

Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access


Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025
News | June 16, 2025

Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025

Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies


Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration
News | June 05, 2025

Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration

BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types


Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
News | February 15, 2025

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab


Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024
News | November 14, 2024

Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024

Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS


FDA approves Bristol Myers Squibb’s Cobenfy
Drug Approval | September 28, 2024

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults